Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
2013.
Rivastigmine.
Reactions Weekly,
Vol. 1464,
Issue. 1,
p.
35.
Ku, Shih-Chieh
Hsu, Chung-Chih
Chang, Hsin-An
Kao, Yu-Chen
and
Tzeng, Nian-Sheng
2014.
Psychotic Episode in a Patient With Alzheimer’s Dementia While Shifting From the Oral to Patch Form of Rivastigmine.
The Journal of Neuropsychiatry and Clinical Neurosciences,
Vol. 26,
Issue. 3,
p.
E51.
Zádori, Dénes
Veres, Gábor
Szalárdy, Levente
Klivényi, Péter
and
Vécsei, László
2015.
Drug-induced movement disorders.
Expert Opinion on Drug Safety,
Vol. 14,
Issue. 6,
p.
877.
Diaz, Maria Cristina B.
and
Rosales, Raymond L.
2015.
A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease.
Medicine,
Vol. 94,
Issue. 34,
p.
e1364.
Bello, Nicholas T.
2015.
A worldwide yearly survey of new data in adverse drug reactions.
Vol. 37,
Issue. ,
p.
1.
Meppelink, Anne Marthe
and
Edwards, Mark J.
2015.
Medication-Induced Movement Disorders.
p.
20.
Değirmenci, Yıldız
and
Keçeci, Hulusi
2016.
Visual Hallucinations Due to Rivastigmine Transdermal Patch Application in Alzheimer's Disease; The First Case Report.
International Journal of Gerontology,
Vol. 10,
Issue. 4,
p.
240.
Ostroumova, T. M.
Tolmacheva, V. A.
Ostroumova, O. D.
and
Parfenov, V. A.
2020.
Drug-induced dystonia.
Neurology, Neuropsychiatry, Psychosomatics,
Vol. 12,
Issue. 5,
p.
4.
Wang, Yi
Wang, Kaiyue
Yan, Junyuan
Zhou, Qian
and
Wang, Xiaoying
2022.
Recent Progress in Research on Mechanisms of Action of Natural Products against Alzheimer’s Disease: Dietary Plant Polyphenols.
International Journal of Molecular Sciences,
Vol. 23,
Issue. 22,
p.
13886.